Targeting histone methyltransferase EZH2 as cancer treatment

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic alterations are hallmarks of cancer, influencing tumor formation and progression.
• Polycomb Repressive Complex 2 (PRC2), via EZH2, regulates histone H3 lysine 27 trimethylation (H3K27me3), impacting cell stemness and differentiation.
• Mutations in PRC2 components, including EZH2, are frequent in various cancers, highlighting their oncogenic role.

Purpose of the Study:

• To review recent advancements in understanding EZH2's dynamic epigenetic regulation in tumor cells, particularly cancer stem cells (CSCs).
• To discuss the therapeutic potential of targeting EZH2 in cancer treatment.
• To explore the challenges and future perspectives in EZH2-targeted cancer therapies.

Main Methods:

• Review of current literature on EZH2 function, epigenetic modifications, and cancer biology.
• Analysis of recent sequencing data implicating EZH2 mutations in cancer.
• Examination of preclinical and clinical studies on EZH2 inhibitors.

Main Results:

• EZH2 and H3K27me3 play significant roles in conferring stemness and driving plasticity in cancer cells, including CSCs.
• Recurrent mutations in EZH2 are observed across diverse cancer types, underscoring its importance.
• Small molecule inhibitors targeting EZH2 activity have shown promise and are undergoing clinical trials, notably for B-cell lymphoma.

Conclusions:

• EZH2 is a critical epigenetic regulator implicated in cancer development and maintenance, especially within the CSC population.
• Targeting EZH2 represents a promising therapeutic strategy for various cancers.
• Further research is needed to elucidate the precise mechanisms of PRC2 regulation and overcome challenges in EZH2-targeted therapy.